Progress on molecular markers of pancreatic cancer

Current Opinion in Gastroenterology

Volumn 23, Issue 5, 2007, Pages 508-514

  Grote, Tobias ^a   Logsdon, Craig D ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE   (United States)

Author keywords

Biomarker; Molecular marker; Pancreatic cancer

Indexed keywords

ACTZ 14011; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; INDIUM 111; MOLECULAR MARKER; UNCLASSIFIED DRUG;

CYST FLUID; DIAGNOSTIC ACCURACY; GLYCOSYLATION; HUMAN; PANCREAS CANCER; PANCREAS JUICE; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTIGENS, CD; CA-19-9 ANTIGEN; CELL ADHESION MOLECULES; CYTOKINES; DNA METHYLATION; GENETIC MARKERS; GLYCOSYLATION; HUMANS; MICRORNAS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548401651     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282ba5724     Document Type: Review

References (43)

1. Hartwell L, Mankoff D, Paulovich A, et al. Cancer biomarkers: a systems approach. Nat Biotechnol 2006; 24:905-908. This excellent review discusses the various applications of biomarkers and their different requirements.
2. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005; 2:416-422.
3. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006; 5:787-796. This comprehensive review provides an overview about the same topic as the current article.
4. Gold DV, Modrak DE, Ying Z, et al. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24:252-258. This article reports studies with an improved immunoassay for MUC1 that shows promising results and supports the idea that biomarkers better than CA19-9 can be developed.
5. Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34:436-443. This article describes the characterization of CEACAM1 as a biomarker with some promise. This molecule was originally discovered as overexpressed in pancreatic cancer during analysis of gene expression with microarrays and is an example of moving from gene discovery to practical application.
6. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12:442-446. The authors tested a panel of five markers and report the results thoroughly, unfortunately none proved to be superior to CA19-9 even in combination.
7. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007; 34:205-214. This study took a proteomic approach and found new potential markers and validated two of them with a commercially available ELISA.
8. Takehara A, Eguchi H, Ohigashi H, et al. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 2006; 97:1191-1197.
9. Hwang TL, Liang Y, Chien KY, Yu JS. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006; 6:2259-2272.
10. Özkan H, Akar T, Koklu S, Coban S. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 2006; 6:268-272.
11. Wadle A, Kubuschok B, Imig J, et al. Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 2006; 119:117-125.
12. Song J, Patel M, Rosenzweig CN, et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 2006; 52:1045-1053.
13. Bloomston M, Zhou JX, Rosemurgy AS, et al. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res 2006; 66:2592-2599.
14. Marchese R, Muleti A, Pasqualetti P, et al. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 2006; 32:171-177. The authors could not detect any K-ras mutation in circulating DNA from pancreatic cancer patients.
15. Ishizone S, Yamauchi K, Kawa S, et al. Clinical utility of quantitative RT-PCR targeted to alpha1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Sci 2006; 97:119-126. This publication reports an interesting and promising approach even though sensitivity and specificity are not high enough for a single marker.
16. Hoffmann K, Kerner C, Wilfert W, et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007; 13:257-263.
17. Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006; 118:2803-2808.
18. Patwa TH, Zhao J, Anderson MA, et al. Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multilectin fluorescence detection. Anal Chem 2006; 78:6411-6421. This proof of principle study seems to be a promising new approach to detect glycosylation patterns with a microarray platform.
19. Zhao J, Qiu W, Simeone DM, Lubman DM. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res 2007; 6:1126-1138. This article supports the previous one, that glycosylation patterns might be useful as a new type of biomarker.
20. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-5327. This article provides guidelines for the clinical use of biomarkers in colorectal and pancreatic cancer.
21. Chang CY, Huang SP, Chiu HM, et al. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 2006; 53:1-4. The authors provided evidence that CA19-9 is not useful as a population screening marker.
22. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24:2897-2902.
23. Kilic M, Gocmen E, Tez M, et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006; 49:241-244.
24. Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70:255-264. This review gives a nice summary about recent publications on the role of CA19-9 as a prognostic marker.
25. Boeck S, Schulz C, Stieber P, et al. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie 2007; 30:39-42.
26. Tessler DA, Catanzaro A, Velanovich V, et al. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006; 191:191-197.
27. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10:2386-2392.
28. Matsubayashi H, Canto M, Sato N, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006; 66:1208-1217. This solid study might be the basis for the development of a seminal tool in using pancreatic juice for diagnosis.
29. Chen R, Pan S, Yi EC, et al. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006; 6:3871-3879.
30. Chen R, Pan S, Cooke K, et al. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007; 34:70-79.
31. Scarlett CJ, Smith RC, Saxby A, et al. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. Gastroenterology 2006; 130:1670-1678. This well conducted study shows that proteomic techniques can identify peak panels that help to differentiate cancer from benign tissue.
32. Tsiambas E, Karameris A, Dervenis C, et al. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 2006; 7:283-294. The authors highlight the importance of correlating gene and protein expression. Also they discuss the benefits of computer assisted analysis of immunohistochemistry.
33. Giovannetti E, Del TM, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66:3928-3935. This study investigated gemcitabine resistance by analysis of resistance gene expression using PCR, which might be an important step towards personalized medicine.
34. Eloubeidi MA, Jhala D, Chhieng DC, et al. Yield of endoscopic ultrasoundguided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer 2003; 99:285-292.
35. Mishra G, Zhao Y, Sweeney J, et al. Determination of qualitative telomerase activity as an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle aspiration. Gastrointest Endosc 2006; 63:648-654. The combination of cytology with cancer specific markers can increase sensitivity and specificity for diagnosis.
36. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and nonneoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007 [Epub ahead of print]. This comprehensive study emphasized the potential of microRNAs for detection as well as therapeutic targeting.
37. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120:1046-1054. This is an adjacent publication in the same field as the previous article.
38. Kosmahl M, Pauser U, Peters K, et al. Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal. Virchows Arch 2004; 445:168-178.
39. Pelaez-Luna M, Chari ST. Cyst fluid analysis to diagnose pancreatic cystic lesions: an as yet unfulfilled promise. Gastroenterology 2006; 130:1007-1009. This selected summary provides a good discussion about recent articles in the field.
40. van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005; 62:383-389.
41. Kobayashi M, Ueyama Y, Nakanishi H, et al. Immunocytochemical detection using CDX2: An aid for discerning tumor involvement in ascites cytology. Cancer 2006; 108:114-118. This article focuses on a little observed source for biomarker studies.
42. Moparty B, Logrono R, Nealon WH, et al. The role of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration in distinguishing pancreatic cystic lesions. Diagn Cytopathol 2007; 35:18-25.
43. Hanaoka H, Mukai T, Tamamura H, et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol 2006; 33:489-494. This study provides profound data for the use of molecular markers for imaging applications.